HTA168 Data Maturity and Treatment Positioning to Support Reimbursement: The Case for Siltuximab (SYLVANT®) in Australia
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.1626
https://www.valueinhealthjournal.com/article/S1098-3015(22)03831-1/fulltext
Title :
HTA168 Data Maturity and Treatment Positioning to Support Reimbursement: The Case for Siltuximab (SYLVANT®) in Australia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03831-1&doi=10.1016/j.jval.2022.09.1626
First page :
Section Title :
Open access? :
No
Section Order :
11178